Inmune Bio (0Y2) AI Stock Analysis

Company Guidance

Guidance from the call centered on near‑term regulatory and clinical milestones: INmune expects to submit the Ebstracel MAA to the UK MHRA by end‑Q3/early‑Q4 2026, the EMA in early 2027 and a U.S. BLA in Q1 2027, supported by MHRA alignment (CMC/nonclinical/clinical) and a pediatric investigation plan approved in <3 months; a follow‑on phase 3 open‑label confirmatory trial is planned at ~40–45 patients (≈33 already lined up), enrolling ~1–2 patients/week, running ~18 months with six total infusions (three treatment sessions), and data are expected around mid‑2028. Manufacturing and supply metrics include first commercial cord processed at the Cell & Gene Therapy Catapult (Stevenage), transfer of the MSC isolation stage to the intended commercial facility, an expanded Anthony Nolan agreement, and the CORDStrom patent entering the U.S. national phase; XPro progress includes FDA Fast Track and MINDFUL phase 2 imaging results (p=0.0028, Cohen’s d=0.46 ITT and 0.59 in biomarker‑enriched subgroup). Financial guidance/metrics: Q2 net loss ~$1.3M vs $24.5M prior year, R&D benefit ~$0.8M vs $5.8M expense prior, G&A ~$2.3M, cash and equivalents $18.4M as of 6/30/2026 plus ~$4.2M subsequent R&D rebate, cash runway into Q2 2027, burn of ~$1.0–1.5M/month, and ~27.8M shares outstanding; market/pricing figures cited: ~2–3K U.S. RDEB patients, ~800 UK patients, 10–15% severe RDEB, ~60% pediatric, and a target price of ~$400K–$500K per child per year (with PRV valuations discussed in the $150–200M range and company remarks of ~$102–110M).